Eiko Lifesciences Ltd (540204)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Eiko Lifesciences' revenue was ₹16.7 Cr (+56.4% year on year, -8.7% on the previous quarter), and net profit ₹1.5 Cr (+35.9% year on year); the operating margin was 11.6%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹16.7 | +56.4% | -8.7% |
| Operating profit | ₹1.9 | +28.3% | -14.3% |
| Net profit | ₹1.5 | +35.9% | +0.6% |
| EPS (₹) | 0.91 | +37.9% | +0.0% |
| Operating margin | 11.6% | — | — |
📢 Recent Corporate Announcements
Eiko LifeSciences has approved the allotment of 1,50,000 equity shares upon conversion of warrants to promoter entity Lenus Finvest Private Limited at an issue price of Rs 55 per share (face value Rs 10 plus premium Rs 45). The company received the remaining 75% consideration totaling Rs 61.88 lakh (Rs 41.25 per warrant), raising total paid-up equity capital to Rs 14.80 crore across 1.48 crore shares. Following this allotment, Lenus Finvest's holding increased from 17.34% to 18.18%. A significant balance of 24,95,000 warrants remains pending conversion across all holders.
- Allotment of 1,50,000 equity shares to promoter entity Lenus Finvest Private Limited at Rs 55 per share
- Received balance 75% warrant consideration of Rs 61,87,500 (Rs 41.25 per warrant)
- Lenus Finvest holding increased from 17.34% (25,40,472 shares) to 18.18% (26,90,472 shares)
- Paid-up equity capital increased to Rs 14,80,08,540 divided into 1,48,00,854 shares
- A total of 24,95,000 warrants remain pending for conversion
Eiko Lifesciences has issued an update under Regulation 36 of SEBI LODR regarding the dispatch of weblinks and QR codes for its 49th Annual General Meeting (AGM) Notice and FY25-26 Annual Report. The AGM is scheduled to be held on Tuesday, September 22, 2026, at 4:00 PM IST via Video Conferencing. The cut-off date for e-voting eligibility is set for Wednesday, September 16, 2026, with the e-voting window active from September 19 to September 21, 2026. The intimation is an administrative compliance requirement for shareholders whose email addresses were unregistered or bounced.
- 49th Annual General Meeting scheduled for September 22, 2026, at 4:00 PM IST via VC/OAVM
- Cut-off date for remote e-voting set as Wednesday, September 16, 2026
- Remote e-voting window opens on September 19, 2026 (9:00 AM) and closes on September 21, 2026 (5:00 PM)
- Letter sent to shareholders whose email addresses were bounced, invalid, or unregistered as of August 21, 2026
Eiko LifeSciences submitted its 49th Annual Report for FY 2025-26, convening its AGM on September 22, 2026. The report recaps consolidated FY26 revenue of ₹52.57 crore and PAT of ₹3.58 crore (up >100% YoY from ₹1.74 crore in FY25) with an EBITDA margin of 11.19%. Key strategic milestones highlighted include the acquisition of a 51% stake in SSM Formulations for ~₹18.15 crore and the preferential allotment of 29,50,000 warrants and 6,25,000 equity shares to fund growth.
- 49th Annual General Meeting scheduled for September 22, 2026 via Video Conferencing.
- FY26 consolidated revenue stood at ₹5,257.14 lakhs with PAT rising over 100% to ₹358.11 lakhs (vs ₹174.08 lakhs in FY25).
- Acquired a 51% controlling stake in SSM Formulations Private Limited for ~₹18.15 crore.
- Allotted 29,50,000 convertible warrants and 6,25,000 equity shares on a preferential basis during the year.
Eiko LifeSciences Limited has issued the notice for its 49th Annual General Meeting scheduled for September 22, 2026, via video conferencing. Key resolutions include the adoption of FY26 financial statements, re-appointment of Director Bhavesh Dhirajlal Tanna (holding 5.86%), and appointment of Suraj Mahadev Gaikwad as an Independent Director for 5 years. Additionally, the company seeks shareholder approval for material related party transactions with limits up to ₹50 crore each across various subsidiary and associate entities, which are substantial compared to its TTM revenue of ₹59 crore.
- 49th AGM scheduled for September 22, 2026 at 04:00 PM IST via VC/OAVM
- Approval sought for appointment of Suraj Mahadev Gaikwad as Independent Director for a 5-year term
- Re-appointment of Bhavesh Dhirajlal Tanna as Director liable to retire by rotation (holds 8,40,000 shares or 5.86% stake)
- Approval sought for Material Related Party Transactions with limits up to ₹50 Crores each for entities including EikoVivify Logistics, Eiko Scientific Solutions, and SSM Formulations
Eiko Lifesciences Limited has announced the resignation of Ms. Hasti Doshi (DIN: 10757758) from the position of Independent Director, effective from the close of business hours on August 24, 2026. Her tenure was originally slated to conclude on September 3, 2029, but she stepped down early citing other career commitments. The filing confirms there are no other material reasons for her departure, and she holds directorships in nil other listed entities.
- Independent Director Ms. Hasti Doshi resigned with effect from the close of business hours on August 24, 2026.
- Tenure was originally scheduled to end on September 3, 2029, cut short due to career commitments.
- Directorships and committee positions in other listed entities reported as NIL.
- Confirmed that there are no material reasons for the resignation other than stated.
Eiko Lifesciences has appointed Mr. Suraj Mahadev Gaikwad as an Additional Director (Independent and Non-Executive) effective August 24, 2026. He will hold office until the upcoming Annual General Meeting (AGM) and, subject to shareholder approval, for a subsequent term of 5 years. Mr. Gaikwad is a Commerce Graduate with over 7 years of experience in accountancy and business management. The appointment is a routine governance and board strengthening action for the Rs 77 crore market-cap company.
- Appointment of Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive) effective August 24, 2026
- Proposed tenure of 5 years following the ensuing AGM, subject to shareholder approval
- Profile includes over 7 years of professional experience in accountancy and business management
- No inter-se relationship with any existing directors of the company
Eiko Lifesciences Limited held a Board meeting on August 24, 2026, noting the resignation of Ms. Hasti Doshi as Independent Director due to career commitments. The Board approved the appointment of Mr. Suraj Mahadev Gaikwad as Additional Independent Director for a 5-year term, subject to shareholder approval. In addition, the 49th Annual General Meeting has been scheduled for September 22, 2026.
- Independent Director Ms. Hasti Doshi stepped down effective closure of business hours on August 24, 2026
- Mr. Suraj Mahadev Gaikwad appointed as Additional Independent Director for a proposed 5-year term
- 49th Annual General Meeting scheduled for September 22, 2026 at 04:00 PM via video conferencing
Eiko LifeSciences has received recovery proceedings from IDBI Bank regarding an alleged corporate guarantee of ₹58 lakh purportedly issued in 1986 by its erstwhile entity, Narendra Investments (Delhi) Limited. The guarantee relates to facilities extended to Consolidated Steels & Alloys Limited nearly four decades ago. The company disputes the claim entirely, has not acknowledged liability, and is initiating legal remedies. Management does not expect any material financial impact on ongoing operations, as the disputed ₹58 lakh represents less than 1% of net worth.
- IDBI Bank initiated recovery proceedings over an alleged ₹58 lakh corporate guarantee
- The transaction dates back nearly 40 years to 1986 under erstwhile Narendra Investments (Delhi) Ltd
- Related to financial facilities provided to Consolidated Steels & Alloys Limited
- Management has disputed the claim and expects no material financial impact
Eiko LifeSciences Limited approved the allotment of 3,05,000 equity shares of face value ₹10 at an issue price of ₹55 per share (including ₹45 premium) upon warrant conversion. The company received ₹1,25,81,250 representing the final 75% balance (₹41.25 per warrant). Promoter Bhavesh Dhirajlal Tanna converted 1,30,000 warrants (raising his stake from 5.86% to 6.62%), while non-promoter V Square Pharmachem converted 1,75,000 warrants (taking a 1.19% stake). Post-allotment, paid-up share capital increases to ₹14.65 crore (1,46,50,854 shares), with 26,45,000 total warrants still outstanding for conversion.
- Allotted 3,05,000 equity shares of ₹10 face value at an issue price of ₹55 each
- Received balance 75% consideration aggregating to ₹1,25,81,250 (₹41.25 per warrant)
- Promoter Bhavesh Dhirajlal Tanna stake rises from 5.86% to 6.62% (allotted 1,30,000 shares)
- Non-promoter V Square Pharmachem allotted 1,75,000 shares (1.19% post-issue holding)
- 26,45,000 total warrants remain pending conversion across holders
Eiko Lifesciences reported a strong year-on-year performance for Q1 FY27, with consolidated revenue rising 56.4% to Rs 16.75 Cr compared to Rs 10.71 Cr in Q1 FY26. Consolidated Net Profit grew 35% YoY to Rs 1.51 Cr, supported by the scaling of its core Specialty Chemicals business and a new contribution from the Logistics segment. However, on a sequential basis, revenue declined 8.7% from Rs 18.34 Cr in Q4 FY26, while PAT remained relatively flat. The new Logistics segment contributed Rs 1.50 Cr to the top line with a healthy segment margin of 19.2%.
- Consolidated Revenue from operations increased 56.4% YoY to Rs 16.75 Cr.
- Consolidated Net Profit rose to Rs 1.51 Cr, up from Rs 1.12 Cr in the year-ago period.
- The new Logistics Services segment contributed Rs 1.50 Cr to revenue and Rs 0.29 Cr to segment profits.
- Specialty & Fine Chemicals segment revenue grew 81.5% YoY to Rs 15.25 Cr.
- Basic EPS for the quarter improved to Rs 0.91 from Rs 0.66 in Q1 FY26.
Eiko Lifesciences has scheduled a board meeting for August 12, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company enters this quarter following a strong FY26, where annual revenue grew 40% to ₹52.71 cr and net profit increased significantly to ₹5.33 cr. Investors will be monitoring if the high revenue run rate of ₹18.34 cr achieved in Q4 FY26 is sustainable. The trading window for designated persons has been closed since July 1, 2026.
- Board meeting scheduled for August 12, 2026, to approve Q1 results.
- Results cover the three-month period ending June 30, 2026.
- Trading window closed from July 1, 2026, until 48 hours post-announcement.
- Company reported a TTM revenue of ₹53 cr and OPM of 14.1% as of March 2026.
- Promoter holding has marginally increased to 39.91% as of March 2026.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
